Interdisciplinary Endoscopy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Gastroenterology and Hepatology, VA White River Junction/Dartmout Hitchcock Medical Center, White River Junction, Vermont, USA.
Gut. 2021 Feb;70(2):268-275. doi: 10.1136/gutjnl-2020-320984. Epub 2020 May 14.
Adenoma detection rate (ADR) has been shown to correlate with interval cancers after screening colonoscopy and is commonly used as surrogate parameter for its outcome quality. ADR improvements by various techniques have been studied in randomised trials using either parallel or tandem methodololgy.
A systematic literature search was done on randomised trials (full papers, English language) on tandem or parallel studies using either adenoma miss rates (AMR) or ADR as main outcome to test different novel technologies on imaging (new endoscope generation, narrow band imaging, iScan, Fujinon intelligent chromoendoscopy/blue laser imaging and wide angle scopes) and mechanical devices (transparent caps, endocuff, endorings and balloons). Available meta analyses were also screened for randomised studies.
Overall, 24 randomised tandem trials with AMR (variable definitions and methodology) and 42 parallel studies using ADR (homogeneous methodology) as primary outcome were included. Significant differences in favour of the new method were found in 66.7% of tandem studies (8222 patients) but in only 23.8% of parallel studies (28 059 patients), with higher rates of positive studies for mechanical devices than for imaging methods. In a random-effects model, small absolute risk differences were found, but these were double in magnitude for tandem as compared with parallel studies (imaging: tandem 0.04 (0.01, 0.07), parallel 0.02 (0.00, 0.04); mechanical devices: tandem 0.08 (0.00, 0.15), parallel 0.04 (0.01, 0.07)). Nevertheless, 94.2% of missed adenomas in the tandem studies were small (<1 cm) and/or non-advanced.
A tandem study is more likely to yield positive results than a simple parallel trial; this may be due to the use of different parameters, variable definitions and methodology, and perhaps also a higher likelihood of bias. Therefore, we suggest to accept positive results of tandem studies only if accompanied by positive results from parallel trials.
腺瘤检出率(ADR)已被证明与筛查结肠镜后的间隔期癌症相关,通常被用作其结果质量的替代参数。已经在使用平行或串联方法学的随机试验中研究了各种技术的 ADR 改善。
系统地对随机试验(全文,英语)进行了文献检索,这些试验使用腺瘤漏检率(AMR)或 ADR 作为主要结局,以测试成像新技术(新型内镜、窄带成像、iScan、Fujinon 智能 chromoendoscopy/blue laser imaging 和广角镜)和机械装置(透明帽、endo 袖口、endoring 和气球)。还对现有的荟萃分析进行了筛选,以寻找随机研究。
总共纳入了 24 项使用 AMR(不同定义和方法学)的随机串联试验和 42 项使用 ADR(方法学一致)作为主要结局的平行试验。在 8222 例患者的串联研究中,有 66.7%(8222 例)发现了有利于新方法的显著差异,但在 28059 例患者的平行研究中,只有 23.8%(28059 例)发现了有利于新方法的显著差异,机械装置的阳性研究比例高于成像方法。在随机效应模型中,发现了小的绝对风险差异,但与平行研究相比,这些差异在串联研究中要大两倍(成像:串联 0.04(0.01,0.07),平行 0.02(0.00,0.04);机械装置:串联 0.08(0.00,0.15),平行 0.04(0.01,0.07))。然而,在串联研究中,94.2%的漏检腺瘤较小(<1cm)且/或非进展性。
与简单的平行试验相比,串联研究更有可能产生阳性结果;这可能是由于使用了不同的参数、变量定义和方法学,并且可能也存在更高的偏倚可能性。因此,我们建议只有在平行试验也产生阳性结果的情况下,才接受串联研究的阳性结果。